Big Biotech Biogen is venturing into the city, paying $16 million in cash to partner up with an RNAi company to build ...

Alnylam Pharmaceuticals ALNY focuses on developing novel therapeutics based on RNAi technology.The company’s pipeline of ...

In addition, we are on track to meet our ambitious pipeline and platform expansion ... Advancements Demonstrate Durable Leadership in TTR Alnylam scientists will provide an update on the TRITON ...

More than 15 candidates to enter the clinic by the end of 2025 Alnylam’s pipeline is advancing rapidly and the company expects to have more than 15 new candidates in the clinic by the end of ...

Alnylam Pharmaceuticals ALNY focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of experimental RNAi therapeutics is focused on three strategic therapeutic ...

Alnylam Pharmaceuticals (ALNY), a commercial-stage company, focuses on developing novel therapeutics based on RNAi. The company’s pipeline of experimental RNAi therapeutics is focused across ...

Axsome Therapeutics (NASDAQ: AXSM), and Summit Therapeutics (NASDAQ: SMMT). (Alnylam Pharmaceuticals): In her comments ...

Moving onto the pipeline updates, Alnylam’s Alzheimer’s program showed promising reductions. Furthermore, the next-gen TTRsc04 Ph1 data, expected by year-end, might show higher knockdown than ...

We continue to have a positive long-term outlook for Alnylam thanks to the continued progression of its diverse drug pipeline for many rare diseases with high unmet needs, which will likely ...

including the commercial launch of the fifth Alnylam-discovered product within four years, while advancing an organic pipeline of potentially transformative investigational medicines in both rare ...

“Alnylam continues to drive the next wave of RNAi therapeutics that is changing medicine, with a sustainable innovation engine generating a robust pipeline and a multi-product commercial ...